Clinical Trial Update: Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008) [Phase 2]

View source ↗

Summary

Clinical trial update on a phase 2 evaluation of a co-formulated pembrolizumab and quavonlimab (MK-1308A) versus other treatments in MSI-H/dMMR stage IV colorec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Quavonlimab (MK-1308)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Colorectal Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING